Drug Trial Radar · NCT07044687
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jul 24, 2025
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jul 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo standard induction therapy, the current standard of care. This study will assess the change in disease activity and adverse events in adult participants with acute myeloid leukemia (AML) being treated with of the combination of azacitidine and venetoclax, in India. The combination of azacitidine and venetoclax is being evaluated in the treatment of acute myeloid leukemia (AML). Participants will receive azacitidine with increasing doses of venetoclax. Around 40 adult participants with a diagnosis of AML will be enrolled in the study at approximately 15 sites in India. Participants will receive venetoclax oral tablets once daily in increasing doses until the study dose is achieved. Then ventoclax oral tablets will continue once daily thereafter. Azacitidine will be given by subcutaneous (SC) or intravenous (IV) injection on Days 1-7 of each cycle. The total study duration is approximately 29 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.
Conditions
- Acute Myeloid Leukemia
Interventions
VenetoclaxDrug
Oral Tablet
AzacitidineDrug
Subcutaneous (SC) Injection
AzacitidineDrug
Intravenous (IV) Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Treatment Emergent Adverse Events (TEAE)sTime frame: Up to Approximately 29 Months
- Percentage of Participants with Post-Baseline Laboratory AbnormalitiesTime frame: Up to Approximately 29 Months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Fortis Memorial Research Institute /ID# 268697
Gurgaon, Haryana, India · Completed
Healthcare Global Enterprises Limited (HCGEL) /ID# 272071
Bengaluru, Karnataka, India · Completed
Mazumdar Shaw Medical Center /ID# 270677
Bengaluru, Karnataka, India · Recruiting
Regional Cancer Centre /ID# 268785
Thiruvananthapuram, Kerala, India · Recruiting
Tata Memorial Hospital - Mumbai /ID# 269177
Mumbai, Maharashtra, India · Recruiting
LMMF's Deenanath Mangeshkar Hospital & Research Center /ID# 268781
Pune, Maharashtra, India · Recruiting
Sahyadri Super Speciality Hospital /ID# 272074
Pune, Maharashtra, India · Recruiting
All India Institute Of Medical Sciences - New Delhi /ID# 268357
New Delhi, National Capital Territory of Delhi, India · Recruiting
Rajiv Gandhi Cancer Institute And Research Centre /ID# 268293
New Delhi, National Capital Territory of Delhi, India · Completed
All India Institute Of Medical Sciences - Bhubaneswar /ID# 274879
Bhubaneswar, Odisha, India · Recruiting
Apollo Cancer Centre /ID# 268780
Chennai, Tamil Nadu, India · Recruiting
Cancer Institute (Wia) /ID# 268695
Chennai, Tamil Nadu, India · Recruiting
Christian Medical College Vellore /ID# 279587
Vellore, Tamil Nadu, India · Recruiting
Basavatarakam Indo American Cancer Hospital & Research Institute /ID# 268692
Hyderabad, Telangana, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.